Manulife Hong Kong and Hong Kong Association of Athletics Affiliates form partnership to establish the Manulife GBA HK-Zhuhai-Macao Bridge Half-Marathon
HONG KONG, Aug. 16, 2022 /PRNewswire/ -- Manulife Hong Kong and the Hong Kong Association of Athletics Affiliates (HKAAA) today jointly announced the signing of a Memorandum of Understanding for a partnership that will bring the first-ever Manulife GBA HK-Zhuhai-Macao Bridge (HZMB) Half-Marathon to life. The HZMB is an iconic structure that connects three of the major cities in the Greater Bay...
ExoCoBio’s First Global Regenerative Aesthetic Exosome Summit
World First Regenerative Aesthetic Exosome Summit (RAES 2022) Participation of Global Exosome and Regenerative Aesthetic Authorities Plan to Grow into a Global Platform for Exosome and Regenerative Aesthetic Industry in the Future SEOUL, South Korea, Aug. 16, 2022 /PRNewswire/ -- ExoCoBio will hold the world first "Regenerative Aesthetic Exosome Summit 2022" (hereinafter the "Summit") under...
Sirnaomics Develops Peptide Docking Vehicle (PDoV(TM)) Designed for an Enhanced GalNAc Delivery Platform for Novel siRNA Therapeutics
A proprietary GalNAc delivery system with enhanced Endosome Escape and Dual-Targeting GAITHERSBURG, Md. and SUZHOU, China, Aug. 16, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that the Company has developed a Peptide Docking Vehicle (PDoV™) to achieve a peptide-enhanced GalNAc platform for...
J INTS BIO, Oral presentation of Preclinical results of its Novel Oral 4th Generation EGFR TKI ‘JIN-A02’ at the 2022 World Conference on Lung Cancer in Vienna, Austria (IASLC...
SEOUL, South Korea, Aug. 16, 2022 /PRNewswire/ -- J INTS BIO announced that the pre-clinical data of its novel, orally administered 4th generation EGFR TKI 'JIN-A02' was presented on the 8th of August, at the 2022 IASLC World Conference on Lung Cancer held in Vienna, Austria, during the official session entitled "Overcoming Resistance to EGFR Inhibitors". ...
ICP DAS – BMP will attend MEDICAL MANUFACTURING ASIA 2022 in Singapore
TAIPEI, Aug. 16, 2022 /PRNewswire/ -- ICP DAS - BMP (Biomedical Polymers), a Taiwanese medical TPU (thermoplastic polyurethane) supplier, will exhibit at MEDICAL MANUFACTURING ASIA 2022, the 5th Manufacturing Processes for Medical Technology Exhibition and Conference, which provides excellent business opportunities in medical technology in the Southeast Asian market. The exhibition will take place at the Marina Bay Sands...
Antengene Announces First Patient Dosed of Small Molecule ATR ATG-018 for the Treatment of Patients with Advanced Solid Tumors and Hematologic Malignancies in Australia
ATG-018, a global rights asset developed by Antengene's internal R&D team, is an orally-bioavailable, small molecule ataxia telangiectasia and Rad3-associated (ATR) kinase inhibitor that targets the DNA damage response (DDR) pathways. The Phase I study will evaluate the safety, pharmacology and preliminary efficacy of ATG-018 monotherapy in patients with advanced tumors...
Bridge Biotherapeutics Receives FDA Authorization to Proceed with Phase 2 Study of BBT-877
BBT-877 is intended to explore its treatment efficacy in idiopathic pulmonary fibrosis patients in a Phase II trial expected to start in 2022 SEONGNAM, South Korea, Aug. 16, 2022 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotechnology company developing novel drugs for cancer, fibrosis and inflammation, announced it has received notice from the U.S. Food...
Gannex Announces First Subject Dosed in the U.S. Drug-Drug Interaction Study of FXR Agonist ASC42 for Treatment of Primary Biliary Cholangitis
-- Enrollment of the total 12 subjects is expected to be completed in August 2022 -- The DDI study on ASC42 in the U.S. is expected to be completed by the beginning of the fourth quarter 2022 -- This DDI study and ongoing Phase II clinical trial in PBC patients in China will provide more evidence to support...
Everest Medicines Enters into Agreement with Gilead Sciences for Trodelvy in Asia Territories
Everest to receive total considerations of up to $455 million with $280 million in upfront payments Broadens development and access to Trodelvy for patients in Greater China and certain Asia Pacific Markets Strengthens balance sheet and streamlines resources to advance robust pipeline of first-in-class and best-in-class drug candidates, and expand product portfolio through strategic transactions and internal drug discovery...
Novavax Nuvaxovid™ COVID-19 Vaccine Approved in South Korea for Use in Adolescents Aged 12 Through 17
Novavax and partner SK bioscience will provide the first protein-based COVID-19 vaccine approved for use in adolescents aged 12 through 17 years in South Korea GAITHERSBURG, Md., Aug. 12, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious...
